On Monday, Heron Therapeutics Inc (NASDAQ: HRTX) was 6.54% up from the session before settling in for the closing price of $1.07. A 52-week range for HRTX has been $1.04 – $3.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 17.85% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 83.75%. With a float of $151.01 million, this company’s outstanding shares have now reached $152.09 million.
In an organization with 126 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 67.55%, operating margin of -17.61%, and the pretax margin is -19.0%.
Heron Therapeutics Inc (HRTX) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Heron Therapeutics Inc stocks. The insider ownership of Heron Therapeutics Inc is 0.71%, while institutional ownership is 80.23%.
Heron Therapeutics Inc (HRTX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 83.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 47.50% during the next five years compared to 20.01% growth over the previous five years of trading.
Heron Therapeutics Inc (NASDAQ: HRTX) Trading Performance Indicators
You can see what Heron Therapeutics Inc (HRTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.18, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.06 in one year’s time.
Technical Analysis of Heron Therapeutics Inc (HRTX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.69 million. That was inferior than the volume of 2.4 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 12.50%. Additionally, its Average True Range was 0.13.
During the past 100 days, Heron Therapeutics Inc’s (HRTX) raw stochastic average was set at 3.72%, which indicates a significant decrease from 11.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 156.30% in the past 14 days, which was higher than the 94.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7382, while its 200-day Moving Average is $2.5203. However, in the short run, Heron Therapeutics Inc’s stock first resistance to watch stands at $1.1767. Second resistance stands at $1.2133. The third major resistance level sits at $1.2567. If the price goes on to break the first support level at $1.0967, it is likely to go to the next support level at $1.0533. The third support level lies at $1.0167 if the price breaches the second support level.
Heron Therapeutics Inc (NASDAQ: HRTX) Key Stats
There are 152,095K outstanding shares of the company, which has a market capitalization of 175.02 million. As of now, sales total 127,040 K while income totals -110,560 K. Its latest quarter income was 32,810 K while its last quarter net income were -4,850 K.
